智通财经APP获悉，百奥赛图-B(02315)盘中涨超12%，截至发稿，涨9.5%，报25.12港元，成交额 1111.34万港元。 消息面上，据上海证券报，10月16日，记者从中国证监会网站获悉，百奥赛图科创板IPO注册申请获中 国证监会同意。据招股书，本次公司拟IPO募资11.85亿元，其中4.54亿元用于药物早期研发服务平台建 设项目，3.16亿元用于抗体药物研发及评价项目，1.65亿元用于临床前及临床研发项目，2.5亿元用于补 充流动资金。 值得注意的是，百奥赛图近期宣布先后与德国Tubulis及全球领先的科技公司默克达成合作协议。 Tubulis拟引进百奥赛图自主开发的全人抗体推进其ADC产品的研发和商业化。百奥赛图将获得一笔首 付款，还将有权获得开发、监管及商业化里程碑付款以及个位数净销售额分成。与默克的合作则聚焦于 推进开发应用于核酸药物的抗体偶联脂质递送解决方案，例如抗体偶联脂质纳米颗粒（LNP）。 （原标题：港股异动 | 百奥赛图-B(02315)盘中涨超12% 百奥赛图科创板IPO注册申请已获中国证监会同 意） ...

智通财经APP获悉，百奥赛图-B(02315)盘中涨超12%，截至发稿，涨9.5%，报25.12港元，成交额 1111.34万港元。 消息面上，据上海证券报，10月16日，记者从中国证监会网站获悉，百奥赛图科创板IPO注册申请获中 国证监会同意。据招股书，本次公司拟IPO募资11.85亿元，其中4.54亿元用于药物早期研发服务平台建 设项目，3.16亿元用于抗体药物研发及评价项目，1.65亿元用于临床前及临床研发项目，2.5亿元用于补 充流动资金。 值得注意的是，百奥赛图近期宣布先后与德国Tubulis及全球领先的科技公司默克达成合作协议。 Tubulis拟引进百奥赛图自主开发的全人抗体推进其ADC产品的研发和商业化。百奥赛图将获得一笔首 付款，还将有权获得开发、监管及商业化里程碑付款以及个位数净销售额分成。与默克的合作则聚焦于 推进开发应用于核酸药物的抗体偶联脂质递送解决方案，例如抗体偶联脂质纳米颗粒（LNP）。 ...

值得注意的是，百奥赛图近期宣布先后与德国Tubulis及全球领先的科技公司默克达成合作协议。 Tubulis拟引进百奥赛图自主开发的全人抗体推进其ADC产品的研发和商业化。百奥赛图将获得一笔首 付款，还将有权获得开发、监管及商业化里程碑付款以及个位数净销售额分成。与默克的合作则聚焦于 推进开发应用于核酸药物的抗体偶联脂质递送解决方案，例如抗体偶联脂质纳米颗粒（LNP）。 百奥赛图-B(02315)盘中涨超12%，截至发稿，涨9.5%，报25.12港元，成交额1111.34万港元。 消息面上，据上海证券报，10月16日，记者从中国证监会网站获悉，百奥赛图科创板IPO注册申请获中 国证监会同意。据招股书，本次公司拟IPO募资11.85亿元，其中4.54亿元用于药物早期研发服务平台建 设项目，3.16亿元用于抗体药物研发及评价项目，1.65亿元用于临床前及临床研发项目，2.5亿元用于补 充流动资金。 ...

Core Viewpoint - The stock of Baiaosaitu-B (02315) has risen over 5% following the approval of its IPO on the Sci-Tech Innovation Board and recent international collaborations with Merck and Tubulis [1] Group 1: IPO Approval - Baiaosaitu has received approval from the Shanghai Stock Exchange's Sci-Tech Innovation Board for its A-share issuance and listing, as confirmed in the 38th review meeting held on September 24, 2025 [1] Group 2: International Collaborations - The company has entered into agreements with Tubulis, a German firm, to advance the development and commercialization of ADC products using Baiaosaitu's fully human antibodies, which includes an upfront payment and potential milestone payments based on development and sales [1] - Collaboration with Merck focuses on developing antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP) [1]

Core Viewpoint - Baosai Technology-B (02315) has received approval from the Shanghai Stock Exchange's Sci-Tech Innovation Board for its A-share issuance and listing, which has positively impacted its stock price, leading to a rise of over 5% in early trading [1] Group 1: Stock Performance - Baosai Technology-B's stock price increased by 4.87%, reaching HKD 29.26, with a trading volume of HKD 6.36 million [1] Group 2: Corporate Developments - The Shanghai Stock Exchange's Sci-Tech Innovation Board approved Baosai Technology's proposal for A-share issuance and listing during the 38th review meeting held on September 24, 2025 [1] - Baosai Technology has entered into collaboration agreements with Germany's Tubulis and global technology leader Merck. Tubulis aims to utilize Baosai's self-developed fully human antibodies to advance its ADC product development and commercialization, providing Baosai with an upfront payment and potential milestone payments along with a single-digit percentage of net sales [1] - The partnership with Merck focuses on developing antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP) [1]

Core Viewpoint - The company BaiO Saite-B (02315) has received approval from the Shanghai Stock Exchange's Sci-Tech Innovation Board for its A-share issuance and listing, which has positively impacted its stock price, leading to a rise of over 5% in early trading [1] Group 1: Stock Performance - BaiO Saite-B's stock price increased by 4.87%, reaching HKD 29.26, with a trading volume of HKD 6.36 million [1] Group 2: Corporate Developments - The Shanghai Stock Exchange's Sci-Tech Innovation Board Listing Committee approved BaiO Saite-B's proposal for A-share issuance and listing during its 38th review meeting on September 24, 2025 [1] - BaiO Saite-B has entered into collaboration agreements with Germany's Tubulis and global technology leader Merck. Tubulis aims to utilize BaiO Saite-B's self-developed fully human antibodies to advance its ADC product development and commercialization, providing BaiO Saite-B with an upfront payment and potential milestone payments along with a single-digit percentage of net sales [1] - The partnership with Merck focuses on developing antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP) [1]

Group 1 - Recent collaborations and R&D progress by Baiaosaitu (02315) with Merck, Tubulis, and IDEAYA highlight its platform strength in antibody drug development and innovative delivery technologies [1][2] - IDEAYA Biosciences announced the advancement of the bispecific antibody-drug conjugate (bsADC) IDE034 (BCG034), developed on Baiaosaitu's RenLite platform, targeting B7-H3 and PTK7, showing significant efficacy in preclinical tumor models [1] - IDEAYA plans to submit a new drug clinical trial application in Q4 of this year, targeting multiple cancers including lung cancer and colorectal cancer [1] Group 2 - Baiaosaitu has entered into agreements with Tubulis and Merck, with Tubulis aiming to utilize Baiaosaitu's fully human antibodies for its ADC product development and commercialization [2] - Baiaosaitu will receive an upfront payment from Tubulis, along with potential milestone payments and a share of net sales [2] - The collaboration with Merck focuses on developing antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP) [2]

Core Insights - Baiaosaitu (02315) has recently announced multiple collaborations and R&D advancements with Merck, Tubulis, and IDEAYA, highlighting its platform strength in antibody drug development and innovative delivery technologies [1][2] Group 1: Collaborations and Partnerships - Baiaosaitu's partner IDEAYA Biosciences unveiled the bispecific antibody-drug conjugate (bsADC) IDE034 (BCG034) during its tenth anniversary R&D day, which targets B7-H3 and PTK7, demonstrating significant efficacy in specific tumor models [1] - The collaboration with Tubulis involves the introduction of Baiaosaitu's fully human antibodies to advance ADC product development and commercialization, with Baiaosaitu set to receive an upfront payment and potential milestone payments [2] - The partnership with Merck focuses on developing antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP) [2] Group 2: Product Development and Clinical Trials - The IDE034 drug, developed on Baiaosaitu's RenLite® platform, is expected to cover multiple indications, including lung cancer and colorectal cancer, with a clinical trial application planned for submission in Q4 of this year [1]

Core Viewpoint - Baiaosaitu-B (02315) has seen a significant stock price increase, with a rise of over 15% in early trading, currently up 11.41% at HKD 27.74, with a trading volume of HKD 12.0264 million [1] Group 1: IPO and Fundraising - The Shanghai Stock Exchange's listing review committee announced that Baiaosaitu's IPO on the Sci-Tech Innovation Board will be reviewed on September 24 [1] - The company plans to raise HKD 1.185 billion through this IPO, which will be allocated to the construction of an early drug development service platform, antibody drug research and evaluation projects, preclinical and clinical research projects, and to supplement working capital [1] Group 2: Collaboration with Merck - Earlier this month, Baiaosaitu signed an antibody selection assessment agreement with Merck, a leading global technology company, to advance the development of antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP) [1] - Under the agreement, Baiaosaitu will provide fully human antibodies developed on its RenMice platform for Merck to evaluate their feasibility for use in antibody-conjugated LNP formulation services [1] - Merck has been granted exclusive rights to acquire selected antibody asset rights, while Baiaosaitu is entitled to receive corresponding fee payments, sales shares, and sublicensing shares [1]

Core Viewpoint - The stock of Baiaosaitu-B (02135) has seen a significant increase of over 7% in the afternoon trading session, attributed to recent licensing agreements with Tubulis and Merck, highlighting the company's competitive edge in the antibody development sector [1] Group 1: Licensing Agreements - On September 16, Baiaosaitu announced a licensing agreement with German ADC developer Tubulis, utilizing its proprietary RenMice fully human antibody development platform for innovative ADC therapies [1] - Under the agreement with Tubulis, Baiaosaitu will receive an upfront payment, milestone payments related to development, regulatory, and commercialization, as well as a single-digit percentage of net sales [1] - Earlier, on September 4, Baiaosaitu signed an antibody option and evaluation agreement with Merck, focusing on evaluating antibodies developed from the RenMice platform for advanced solutions like nucleic acid drug delivery [1] Group 2: Market Performance - As of the report, Baiaosaitu's stock price is at 26.58 HKD, with a trading volume of 16.7354 million HKD, reflecting a 4.07% increase at the time of publication [1] - The recent agreements with Tubulis and Merck underscore the international competitiveness and drug conversion potential of Baiaosaitu's fully human antibody platform, as stated by the company's Chairman and CEO, Shen Yulei [1]